ADVENTRX Pharmaceuticals, Inc. company was founded in 1995 is based in San Diego, California. ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

Genetic Technologies Limited operates as a life science company, specializing in the fields of genetics and genomics primarily in Australia. The company provides genetic testing services to human beings for disease susceptibility, parentage, individual identity, forensics, and sports performance; animals, such as dogs, horses, birds, alpacas, exotics, and zoo animals for parentage, pedigree, traits, and disease susceptibility; and plants for traits and disease susceptibility. It also offers canine reproductive services, as well as involves in licensing its non-coding DNA patents. The company was formerly known as Duketon Goldfields N.L. and changed its name to Genetic Technologies Limited in August 2000. Genetic Technologies Limited was incorporated in 1987 and is based in Fitzroy, Australia.

MIGENIX likes to pick up compounds after they've been discovered, and shepherd them through to late-stage clinical development. After that point, the company is happy to license them out and hopefully reap the benefits. MIGENIX has partnered with Cadence Pharmaceuticals to shoulder the cost of putting its omiganan gel through Phase III clinical trials for use in preventing catheter-related infections. Cutanea Life Sciences holds the rights to develop omiganan as an acne treatment. Other clinical and pre-clinical drug candidates in the company's pipeline include potential treatments for Hepatitis B and C, blood infections, and neuro-degenerative diseases.

Ono Pharmaceutical traces its history back to 1717, though it took its current form in 1947. Ono Pharmaceutical Co., Ltd. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company offers oral medication for the treatment of bronchial asthma, disturbances of peripheral circulation, chronic pancreatitis and overactive bladder, as well as injection drugs for the treatment of acute lung injury, generalized intravascular coagulation syndrome, acute phase cerebral thrombosis and blood pressure regulators used during surgical operations. The Company has four subsidiaries and two associated companies.

Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Its cancer drug Velcade is approved as a treatment for multiple myeloma (a type of blood cancer) and Mantle Cell Lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). The company has more than a dozen other candidates in the pipeline, most of them cancer-related. Millennium's oncology-focused sales force, in partnership with Johnson & Johnson subsidiary Ortho Biotech, sells the drug in the US; Ortho Biotech is responsible for sales in Europe and in other countries where Velcade is approved (except Japan, which is covered by Janssen). Takeda Pharmaceutical acquired Millennium Pharmaceuticals for $8.8 billion in 2008.

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.

Mirari Biosciences was founded in 2000 by CEO Mark Martin, who developed the MASC and Peplica technologies. Mirari Biosciences it working to cut down on the time its takes to test new drugs. The first of the company's two primary technologies is microwave-accelerated surface chemistry (MASC) which can speed up drug discovery tests, medical and veterinary diagnostics, and food and water testing by exposing test materials to low-heat microwaves. Its protein amplification technology (Peplica) replicates proteins which helps researchers locate and identify minute levels of proteins.

Archemix Corp., a biotechnology company, engages in discovering, developing, and commercializing aptamer therapeutics for the prevention and treatment of chronic and acute diseases in Massachusetts. The company’s aptamer product candidates include ARC1779 for thrombotic microangiopathyies and carotid endarterectomy surgical procedure. It also offers product candidates for cardiovascular, hematology, and oncology diseases. Archemix Corp. was incorporated in 2000 and is based in Cambridge, Massachusetts.

Marshall Edwards, Inc. was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited. Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol.

Paladin Labs Inc. company's slate of prescription offerings includes drugs for urology, endocrinology, cancer, dermatology, neurology, and women's health. Among Paladin's key products are prostate cancer treatment Trelstar, testosterone deficiency drug Testim, and osteoarthritis therapy Pennsaid. The company also offers some over-the-counter (OTC) drugs in Canada, including emergency contraceptive Plan B. The company focuses on serving markets that are overlooked by larger pharmaceutical firms, typically by forming developing and marketing partnerships with other drugmakers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.